Transgene SA Resumes Trading After €105 Million Capital RaiseTransgene SA resumes trading after a €105 million capital raise, boosting its cancer vaccine pipeline and expanding its virus‑based research platform.Transgene SA Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 27/11/2025, 00:18 2 minutes to read